Compare VNT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNT | RYTM |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.8B |
| IPO Year | 2020 | 2017 |
| Metric | VNT | RYTM |
|---|---|---|
| Price | $36.63 | $85.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $46.89 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 764.7K | 752.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | 0.36 | ★ 28.34 |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $3,075,600,000.00 | N/A |
| Revenue This Year | $2.39 | $55.34 |
| Revenue Next Year | $4.19 | $86.06 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $30.67 | $55.31 |
| 52 Week High | $48.20 | $122.20 |
| Indicator | VNT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 46.57 |
| Support Level | $36.45 | $82.98 |
| Resistance Level | $37.94 | $90.79 |
| Average True Range (ATR) | 0.89 | 3.43 |
| MACD | 0.11 | 0.34 |
| Stochastic Oscillator | 54.55 | 35.25 |
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2025.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.